APLIF News and Press, Appili Therapeutics Inc From 11/14/22

Appili Therapeutics ( OTCQX:APLIF ) has announced that the U.S. Department of Defense will provide at least $14M in funding over two years to fund the development of ATI-1701. ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with aerosol...

Dr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and Chief Executive Officer of Appili Appili Therapeutics Inc. (TSX: APLI; OTCQ...

Appili Therapeutics press release ( OTCQX:APLIF ): Q2 GAAP EPS of -C$0.04. As of September 30, 2022, the Company had cash of C$2.4 million, compared to C$6.7 million on March 31, 2022. For further details see: Appili Therapeutics GAAP EPS of -C$0.04

Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501, a liquid oral formulation of the antibiotic metronidazole. ...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders hel...

Appili Therapeutics press release ( OTCQX:APLIF ): Q1 GAAP EPS of -$0.03 misses by $0.01 . As of June 30, 2022, the Company had cash and short-term investments of $5.55 million, compared to $6.66 million on March 31, 2022. For further details see: Appili Therapeu...

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its f...

Appili to present update on topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “...

Appili Therapeutics press release ( OTCQX:APLIF ): FY GAAP EPS of -C$0.38. At March 31, 2022, the Company had cash and short-term investments of C$6.7 million compared to C$16.1 million at March 31, 2021. For further details see: Appili Therapeutics GAAP EPS of -C$0....

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended Mar...